LONDON (Reuters) -Drugmaker Novo Nordisk is once again Europe's largest company by market capitalisation, rising above German ...

The major averages posted modest gains on Thursday, catching a tailwind from a cooler-than-anticipated inflation report.

Stifel Nicolaus cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Hsbc Global Res upgraded ... a 12 month high of $148. ...

Wegovy-maker Novo Nordisk has pushed out CEO Lars Fruergaard ... Novo’s shares have plunged since hitting a record high in June last year as competition, particularly from US rival Eli Lilly ...

Under Jorgensen's leadership, Novo Nordisk became a world leader in the lucrative weight-loss drug market, with sky-rocketing sales of its Wegovy and Ozempic treatments. Sign up here. "The changes ...

By Rebecca Robbins Novo Nordisk will replace its chief executive, Lars Fruergaard Jorgensen, the company announced Friday, citing a sharp decline in its stock price that stemmed from increased ...

Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight-loss drugs. The Ozempic maker’s chief executive ...

Novo Nordisk has submitted an "Ozempic pill" to the FDA for approval. The new pill will probably be popular (if approved). However, making it will require Novo Nordisk to ramp up semaglutide ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight loss drugs Ozempic and Wegovy, have been absolutely plummeting. The company's stock price slid over ...

Most people would probably prefer a pill to a needle. Indeed, the stakes are high. Novo Nordisk recently suffered a setback with CagriSema, its next-generation injectable drug in testing to treat ...

By Eshe Nelson Reporting from London Novo Nordisk, the Danish pharmaceutical company behind Ozempic and Wegovy, capped off a somewhat turbulent 2024, reporting profit and revenue on Wednesday that ...